| 2.89 0.49 (20.42%) | 11-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.15 |
1-year : | 4.85 |
| Resists | First : | 3.55 |
Second : | 4.15 |
| Pivot price | 2.63  |
|||
| Supports | First : | 2.67 |
Second : | 2.13 |
| MAs | MA(5) : | 2.41 |
MA(20) : | 2.76 |
| MA(100) : | 6.03 |
MA(250) : | 14.37 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 41 |
D(3) : | 19.5 |
| RSI | RSI(14): 48.3 |
|||
| 52-week | High : | 63.45 | Low : | 1.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SLXN ] has closed below upper band by 24.1%. Bollinger Bands are 66% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.92 - 2.94 | 2.94 - 2.95 |
| Low: | 2.45 - 2.47 | 2.47 - 2.48 |
| Close: | 2.87 - 2.89 | 2.89 - 2.91 |
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Wed, 26 Nov 2025
Silexion Therapeutics (SLXN) sets NobleCon21 presentation on Dec. 3 investor event - Stock Titan
Tue, 25 Nov 2025
Silexion to begin phase 2/3 pancreatic cancer clinical trial in Q2 2026 - MarketScreener
Tue, 25 Nov 2025
Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026 - TradingView
Tue, 25 Nov 2025
Silexion Therapeutics Completes Toxicology Studies for SIL204 - TradingView
Wed, 12 Nov 2025
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 8.4 (%) |
| Shares Short | 146 (K) |
| Shares Short P.Month | 29 (K) |
| EPS | -30.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -32.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -193.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | -0.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|